Leucovorin
Information
- Drug Name
- Leucovorin
- Description
- Entry(CIViC)
- 2
CIViC
| Disease | Mutation | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| colorectal adenocarcinoma |
ERBB2 p.Leu755Ser (p.L755S) ( ENST00000269571.10, ENST00000406381.6, ENST00000445658.6, ENST00000541774.5, ENST00000584450.5, ENST00000584601.5 ) ERBB2 p.Leu755Ser (p.L755S) ( ENST00000269571.10, ENST00000406381.6, ENST00000445658.6, ENST00000541774.5, ENST00000584450.5, ENST00000584601.5 ) |
C |
Predictive
|
Does Not Support
|
Sensitivity/Response | Somatic | 3 | 27626067 | Detail |
| head and neck squamous cell carcinoma |
DPYD EXON 11-19 DELETION ( ENST00000370192.8 ) DPYD EXON 11-19 DELETION ( ENST00000370192.8 ) |
C |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 4 | 31871216 | Detail |
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| Patient was a 35 year old male who was treated wit... | ERBB2 |
ERBB2 p.Leu755Ser (p.L755S) ( ENST00000269571.10, ENST00000406381.6, ENST00000445658.6, ENST00000541774.5, ENST00000584450.5, ENST00000584601.5 ) ERBB2 p.Leu755Ser (p.L755S) ( ENST00000269571.10, ENST00000406381.6, ENST00000445658.6, ENST00000541774.5, ENST00000584450.5, ENST00000584601.5 ) |
Sensitivity | false | CIViC Evidence | detail |
| A 69 year old patient diagnosed with HNSCC present... | DPYD |
DPYD EXON 11-19 DELETION ( ENST00000370192.8 ) DPYD EXON 11-19 DELETION ( ENST00000370192.8 ) |
Sensitivity | true | CIViC Evidence | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02138617 | Active, not recruiting | Phase 2 | Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer | May 2014 | June 1, 2027 |
| NCT03281369 | Active, not recruiting | Phase 1/Phase 2 | A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) | October 13, 2017 | April 30, 2025 |
| NCT03736720 | Active, not recruiting | Phase 2 | Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin | June 17, 2019 | June 17, 2026 |
| NCT04233866 | Active, not recruiting | Phase 2 | Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread | August 26, 2020 | December 31, 2025 |
| NCT03279237 | Active, not recruiting | Phase 1 | A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers | October 24, 2017 | September 2023 |
| NCT03221426 | Active, not recruiting | Phase 3 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) | October 9, 2017 | June 27, 2025 |
| NCT03586869 | Active, not recruiting | Phase 1/Phase 2 | QUILT-3.080: NANT Pancreatic Cancer Vaccine | July 28, 2018 | December 2019 |
| NCT04210115 | Active, not recruiting | Phase 3 | Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975) | February 28, 2020 | February 1, 2027 |
| NCT03563157 | Active, not recruiting | Phase 1/Phase 2 | QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine | May 25, 2018 | December 30, 2022 |
| NCT03493048 | Active, not recruiting | Phase 2 | Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM | April 15, 2018 | June 2025 |
| NCT00136435 | Active, not recruiting | Phase 2 | A Study in Adults With Untreated Acute Lymphoblastic Leukemia | June 2002 | July 2024 |
| NCT03193190 | Active, not recruiting | Phase 1/Phase 2 | A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) | July 5, 2017 | October 31, 2026 |
| NCT04481204 | Active, not recruiting | Phase 2 | New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study | April 18, 2023 | April 6, 2025 |
| NCT02872116 | Active, not recruiting | Phase 3 | Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer | October 12, 2016 | May 31, 2024 |
| NCT04447092 | Active, not recruiting | Phase 2 | Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer | July 1, 2020 | December 31, 2025 |
| NCT02828358 | Active, not recruiting | Phase 2 | Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement | April 1, 2017 | September 22, 2024 |
| NCT00878254 | Active, not recruiting | Phase 2 | Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma | March 25, 2009 | September 2027 |
| NCT02578368 | Active, not recruiting | Phase 3 | Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction | February 2016 | February 2026 |
| NCT03406299 | Active, not recruiting | Phase 2 | Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer | April 19, 2018 | December 31, 2023 |
| NCT04937738 | Active, not recruiting | Phase 2 | Perioperative Chemotherapy in Gastric Cancer | July 21, 2021 | July 1, 2029 |
| NCT02509286 | Active, not recruiting | Phase 3 | Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus | January 2016 | December 31, 2024 |
| NCT04164069 | Active, not recruiting | Phase 1 | Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab | September 2, 2020 | December 31, 2023 |
| NCT00082706 | Active, not recruiting | Phase 2 | Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant | April 23, 2003 | December 31, 2024 |
| NCT04083235 | Active, not recruiting | Phase 3 | A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment | February 11, 2020 | December 31, 2024 |
| NCT04752696 | Active, not recruiting | Phase 2 | Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma | February 3, 2021 | March 11, 2024 |
| NCT03387111 | Active, not recruiting | Phase 1/Phase 2 | QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed | January 13, 2018 | April 2021 |
| NCT05330429 | Active, not recruiting | Phase 2 | Study of Magrolimab Given Together With FOLFIRI/BEV in Patients With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) | July 8, 2022 | November 2026 |
| NCT05568095 | Active, not recruiting | Phase 3 | A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body | November 21, 2022 | May 2026 |
| NCT04882241 | Active, not recruiting | Phase 3 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension | July 29, 2020 | June 27, 2025 |
| NCT04390399 | Active, not recruiting | Phase 2 | Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer | July 21, 2020 | September 30, 2024 |
| NCT05192889 | Active, not recruiting | Phase 1/Phase 2 | Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax | August 25, 2022 | July 2029 |
| NCT03387085 | Active, not recruiting | Phase 1/Phase 2 | QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. | March 16, 2018 | October 2023 |
| NCT04068103 | Active, not recruiting | Phase 2/Phase 3 | Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery | December 16, 2019 | April 30, 2027 |
| NCT05678257 | Active, not recruiting | Phase 2 | A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer | April 18, 2023 | March 2025 |
| NCT01920737 | Active, not recruiting | Phase 2 | A Novel "Pediatric-Inspired" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia | August 2013 | August 2024 |
| NCT03970252 | Active, not recruiting | Early Phase 1 | Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer | July 24, 2019 | April 2026 |
| NCT03929666 | Active, not recruiting | Phase 2 | A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer | August 29, 2019 | October 30, 2026 |
| NCT04251715 | Active, not recruiting | Phase 2 | mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma | April 28, 2021 | November 30, 2024 |
| NCT03817320 | Active, not recruiting | Phase 1/Phase 2 | PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma | February 12, 2019 | June 30, 2025 |
| NCT03785873 | Active, not recruiting | Phase 1/Phase 2 | Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer | May 22, 2019 | May 2025 |
| NCT02008656 | Active, not recruiting | Phase 2 | Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management | November 2013 | November 2024 |
| NCT03329248 | Active, not recruiting | Phase 1/Phase 2 | QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy | November 6, 2017 | December 2020 |
| NCT02436044 | Approved for marketing | HAIC Using Oxaliplatin Plus Fluorouracil/Leucovorin for Patients With Locally Advanced HCC | |||
| NCT00663481 | Completed | Phase 1 | A Clinical Trial of CoFactor Formulations and Leucovorin Administered Intravenously in Healthy, Adult Subjects. | April 2008 | May 2008 |
| NCT00778102 | Completed | Phase 2 | A Study of Avastin (Bevacizumab) in Combination With mFOLFOX-6 or FOLFOXIRI in Patients With Metastatic Colorectal Cancer. | October 2008 | October 2013 |
| NCT00803647 | Completed | Phase 2 | A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver | January 2010 | November 2014 |
| NCT00831181 | Completed | Phase 2 | Neo-adjuvant Chemoradiation With Oxaliplatin/5-FU in Rectal Cancer | July 2004 | November 2009 |
| NCT00932438 | Completed | Phase 1/Phase 2 | Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab | June 2009 | December 2012 |
| NCT00940303 | Completed | Phase 2 | OPAL Study: A Study of Avastin (Bevacizumab) in Combination With FOLFOXIRI in Patients With Previously Untreated Metastatic Colorectal Cancer | June 2009 | February 2014 |
| NCT00941499 | Completed | Phase 1 | Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab | July 2009 | May 2014 |
| NCT00941655 | Completed | Phase 3 | Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial | July 22, 2009 | June 18, 2012 |
| NCT01013805 | Completed | Phase 2 | Preoperative Radiotherapy and Chemotherapy in Patients With Locally Advanced Rectal Cancer | November 2009 | December 2012 |
| NCT01046864 | Completed | Phase 1 | Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI) | February 2010 | June 2014 |
| NCT01060007 | Completed | Phase 2 | Five Fractions of Radiotherapy Followed by Full Dose FOLFOX Chemotherapy as Preoperative Treatment for Rectal Cancer | November 2009 | September 2014 |
| NCT01077739 | Completed | Phase 2 | A Study of Avastin (Bevacizumab) With XELOX or FOLFOX in Patients With Metastatic Colorectal Cancer and Disease Progression Under First-line FOLFIRI and Avastin | July 2009 | January 2012 |
| NCT01102686 | Completed | Phase 1/Phase 2 | Pyrimethamine as a Treatment for Late-Onset GM2-gangliosidosis (Tay-Sachs and Sandhoff Disease) | August 2009 | November 2010 |
| NCT01121848 | Completed | Phase 3 | Randomized Study With Oxaliplatin in 2nd Line Pancreatic Cancer | July 2010 | October 2013 |
| NCT01164215 | Completed | Phase 1 | Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy | February 2010 | September 2013 |
| NCT01183663 | Completed | Phase 1 | Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX) | August 2010 | May 2016 |
| NCT01206530 | Completed | Phase 1/Phase 2 | FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer | September 2010 | September 2017 |
| NCT01216644 | Completed | Phase 2/Phase 3 | 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer | August 2010 | May 2019 |
| NCT01226719 | Completed | Phase 2 | FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only | December 2010 | March 2014 |
| NCT01227707 | Completed | Phase 2 | A Study of Avastin (Bevacizumab) Plus Xeloda (Capecitabine) in Patients With Locally Advanced Rectal Cancer. | November 2005 | August 2010 |
| NCT01246960 | Completed | Phase 2 | A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer | April 2011 | May 2014 |
| NCT01263171 | Completed | Phase 2 | Oxaliplatin, Leucovorin, and Fluorouracil Before and After Radiation Therapy and Surgery in Treating Patients With Rectal Cancer That Can Be Removed by Surgery | April 2012 | November 2015 |
| NCT01274624 | Completed | Phase 1 | Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer | December 2010 | November 2018 |
| NCT01362374 | Completed | Phase 1 | Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors | July 11, 2011 | October 16, 2020 |
| NCT01374425 | Completed | Phase 2 | Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer (mCRC) | August 2011 | July 2015 |
| NCT01413022 | Completed | Phase 1 | FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma | April 2012 | September 2016 |
| NCT01418222 | Completed | Phase 2 | FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer | September 14, 2011 | March 18, 2013 |
| NCT01467115 | Completed | Phase 2 | Induction Chemotherapy Followed by Cetuximab and Radiation Therapy for Head and Neck Cancer | March 2010 | October 7, 2014 |
| NCT01490866 | Completed | Phase 2 | A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC) | January 2012 | July 2015 |
| NCT01494506 | Completed | Phase 3 | Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer | November 2011 | October 2015 |
| NCT01523431 | Completed | Phase 2/Phase 3 | Individual Dosage Selection of Irinotecan (CPT-11) Based on UGT1A1 Genotype in Metastatic Colorectal Cancer Patients | March 8, 2012 | April 27, 2016 |
| NCT01588990 | Completed | Phase 4 | A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer | June 26, 2012 | September 30, 2016 |
| NCT01633970 | Completed | Phase 1 | A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors | July 11, 2012 | February 26, 2020 |
| NCT01652482 | Completed | Phase 2 | Safety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC) | October 2012 | November 2014 |
| NCT01653470 | Completed | Phase 1 | Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors | October 12, 2012 | May 8, 2017 |
| NCT01660711 | Completed | Phase 2 | A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma | July 2012 | August 22, 2018 |
| NCT01670721 | Completed | Phase 3 | Colorectal Cancer Metastatic | August 2012 | June 2015 |
| NCT01715233 | Completed | Phase 2 | Phase II Study Using CHFR Methylation Status in Patients With Metastatic Esophageal, Gastroesophageal, Gastric Cancer. | December 2012 | April 2017 |
| NCT01726452 | Completed | Phase 3 | NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS) | January 24, 2013 | August 4, 2022 |
| NCT01737671 | Completed | Early Phase 1 | Methotrexate Infusion Into the Fourth Ventricle in Children With Malignant Fourth Ventricular Brain Tumors: A Pilot Study | December 27, 2012 | January 11, 2018 |
| NCT01747551 | Completed | Phase 2 | FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer | January 2013 | July 26, 2017 |
| NCT01775501 | Completed | Phase 2 | Sorafenib + mFOLFOX for Hepatocellular Carcinoma | January 2013 | December 2019 |
| NCT01803282 | Completed | Phase 1 | Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors | March 29, 2013 | April 23, 2019 |
| NCT01821612 | Completed | Early Phase 1 | Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients With Pancreatic Cancer | May 2013 | June 15, 2018 |
| NCT01896531 | Completed | Phase 2 | A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer | August 14, 2013 | January 26, 2021 |
| NCT01913639 | Completed | Phase 2 | FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer | July 2013 | June 2019 |
| NCT01926197 | Completed | Phase 3 | Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer | August 14, 2013 | September 30, 2022 |
| NCT01928290 | Completed | Phase 2 | Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer | November 8, 2013 | October 28, 2019 |
| NCT01930552 | Completed | Phase 1 | A Phase I Study of Aflibercept Plus FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) in Chinese Patients With Advanced Solid Malignancies | September 2013 | December 2014 |
| NCT01959139 | Completed | Phase 1/Phase 2 | S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer | January 23, 2014 | November 9, 2023 |
| NCT02024607 | Completed | Phase 1/Phase 2 | A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer | January 2014 | November 2019 |
| NCT00001449 | Completed | Phase 1 | A Phase I Study of Weekly Gemcitabine in Combination With Infusional Fluorodeoxyuridine and Oral Calcium Leucovorin in Adult Cancer Patients | September 1995 | April 2000 |
| NCT00001498 | Completed | Phase 2 | A Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast Cancer | February 1996 | December 2000 |
| NCT00001576 | Completed | Phase 1 | A Phase I Study of Isolated Hepatic Perfusion With Escalating Dose Melphalan Followed by Postoperative Hepatic Arterial Floxuridine and Leucovorin for Metastatic Unresectable Colorectal Cancers of the Liver | July 1997 | March 2002 |
| NCT00001579 | Completed | Phase 1 | A Phase I Trial of 5-Fluorouracil Given With 776C85 (GW776) and Low-Dose Leucovorin in Adult Patients With Solid Tumors | June 1997 | March 2001 |
| NCT00004997 | Completed | Phase 2 | Leucovorin for the Treatment of 5 q Minus Syndrome | April 1998 | July 2002 |
| NCT00009737 | Completed | Phase 3 | A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer | November 1998 | April 2004 |
| NCT00041132 | Completed | Phase 2 | S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell Lymphoma | September 2002 | June 2011 |
| NCT00061815 | Completed | Phase 3 | Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer | March 2003 | November 2005 |
| NCT00069108 | Completed | Phase 3 | A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer | July 2003 | August 2006 |
| NCT00109837 | Completed | Phase 2 | S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | April 2005 | November 2014 |
| NCT00111761 | Completed | Phase 2 | Evaluating Panitumumab (ABX-EGF) in Patients With Metastatic Colorectal Cancer | July 2002 | October 2008 |
| NCT00126256 | Completed | Phase 3 | Trial Comparing Two Strategies of Chemotherapy for Metastatic Colorectal Cancer | February 2002 | February 2006 |
| NCT00133991 | Completed | Phase 2 | Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia | July 2005 | August 2013 |
| NCT00139230 | Completed | Phase 2 | Combination Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck | January 1997 | December 2006 |
| NCT00139243 | Completed | Phase 1/Phase 2 | Study of Taxotere, Cisplatin, 5-Fluorouracil, and Leucovorin for Squamous Cell Carcinoma of the Head and Neck | October 1997 | January 2006 |
| NCT00165178 | Completed | Phase 3 | Treatment of Acute Lymphoblastic Leukemia in Children | September 2000 | May 2011 |
| NCT00176462 | Completed | Phase 2 | CINJALL: Treatment for Children With Acute Lymphocytic Leukemia | February 2001 | September 2008 |
| NCT00176774 | Completed | Phase 2 | Irinotecan, 5-Fluorouracil, and Leucovorin in Colorectal Carcinoma | February 2001 | April 2004 |
| NCT00193219 | Completed | Phase 2 | Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer | July 2005 | July 2010 |
| NCT00199797 | Completed | Phase 1 | Phase I Trial of huA33 Plus Chemotherapy in Patients With Metastatic Colorectal Cancer | April 18, 2005 | April 1, 2016 |
| NCT00209625 | Completed | Phase 1/Phase 2 | Phase I / II Study of Irinotecan (CPT-11) Combined With l-Leucovorin (l-LV) and 5-FU in Patients With Advanced Colorectal Cancer | April 2000 | November 2004 |
| NCT00235898 | Completed | Phase 2 | Clinical Trial in Patients With Metastatic Colorectal Cancer | May 2005 | |
| NCT00252564 | Completed | Phase 3 | Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer | September 2005 | June 2009 |
| NCT00267865 | Completed | Phase 2 | Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma | September 14, 2006 | September 19, 2019 |
| NCT00278889 | Completed | Phase 2 | Second Line ColoRectal Cancer Therapy in Combination With Combination of FOL- Folinic Acid(Leucovorin), F - Fluorouracil and OX - Oxaliplatin (FOLFOX) | January 2006 | October 2009 |
| NCT00305188 | Completed | Phase 3 | Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy. | December 2005 | October 2009 |
| NCT00308516 | Completed | Phase 2 | 5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer | March 2006 | February 2012 |
| NCT00309543 | Completed | Phase 3 | Randomized Trial on Adjuvant Chemotherapy in Colon Carcinoma Dukes B | November 1993 | |
| NCT00321828 | Completed | Phase 2 | Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colon Cancer That Cannot Be Removed By Surgery | March 2006 | December 2012 |
| NCT00354978 | Completed | Phase 2 | Study of FOLFIRI Plus Bevacizumab in Colorectal Cancer Patients | January 2005 | March 2011 |
| NCT00418938 | Completed | Phase 2 | SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial | November 1, 2006 | April 1, 2013 |
| NCT00422864 | Completed | Phase 2 | A Single Arm Trial of Oxaliplatin and 5FU With Concurrent Radiation in Patients With Metastatic Rectal Cancer | October 2006 | January 2011 |
| NCT00447967 | Completed | Phase 2 | Combination of CPT-11 and LoHP vs Combination of 5-FU, Leucovorin and LoHP as 1st Line Treatment in Gastric Patients | July 2004 | September 2008 |
| NCT00448760 | Completed | Phase 2 | Combination Chemotherapy in Treating Patients With Previously Untreated Stage II or Stage III Esophageal Cancer That Can Be Removed By Surgery | October 2004 | April 2010 |
| NCT00450801 | Completed | Phase 2 | R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma | April 2004 | July 2015 |
| NCT00469443 | Completed | Phase 3 | Randomized Phase III Study of Folfiri+Avastin Versus Xeliri+Avastin as 1st Line Treatment of CRC | December 2006 | February 2010 |
| NCT00499850 | Completed | Phase 1 | Phase I FOLFOX Combination | August 2005 | April 2008 |
| NCT00501410 | Completed | Phase 1 | FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer | April 23, 2007 | March 3, 2017 |
| NCT00507091 | Completed | Phase 1 | Phase I Irinotecan, 5-Fluorouracil and Leucovorin Combination | August 2005 | June 2008 |
| NCT00507585 | Completed | Phase 1 | Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, Leucovorin, and Avastin | June 2006 | January 2010 |
| NCT00515216 | Completed | Phase 2 | Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction (GEJ) Tumors | August 2007 | November 2013 |
| NCT00559455 | Completed | Phase 2 | Phase II Study of Eloxatin+5-FU/LV in Patients With Unresectable Hepatocellular Carcinoma | September 2007 | January 2010 |
| NCT00642577 | Completed | Phase 3 | A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Chinese Patients With Metastatic Colorectal Cancer. | July 2007 | December 2010 |
| NCT02124148 | Completed | Phase 1 | A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer | June 18, 2014 | February 13, 2020 |
| NCT02231723 | Completed | Phase 1 | A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer | August 2014 | June 2020 |
| NCT02256800 | Completed | N/A | Escalated Dose of Irinotecan in mCRC | August 13, 2014 | November 30, 2017 |
| NCT02340949 | Completed | Phase 2 | Induction FOLFOX With or Without Aflibercept Followed by Chemoradiation in High Risk Locally Advanced Rectal Cancer | January 2015 | February 4, 2020 |
| NCT02414009 | Completed | Phase 2 | Study to Compare CAPTEM vs FOLFIRI as Second Line Treatment in Advanced, Colorectal Cancer Patients | September 2014 | July 30, 2019 |
| NCT02545504 | Completed | Phase 3 | Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | October 13, 2015 | May 15, 2019 |
| NCT02551991 | Completed | Phase 2 | Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma | October 19, 2015 | February 15, 2021 |
| NCT02620423 | Completed | Phase 1 | Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma | December 2015 | August 2018 |
| NCT02625610 | Completed | Phase 3 | Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100) | December 24, 2015 | June 3, 2021 |
| NCT02641691 | Completed | Phase 2 | Non-Operative Radiation Management of Adenocarcinoma of the Lower Rectum | May 27, 2016 | March 29, 2020 |
| NCT02715531 | Completed | Phase 1 | A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors | April 6, 2016 | May 31, 2021 |
| NCT02735239 | Completed | Phase 1/Phase 2 | Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer | June 24, 2016 | June 16, 2022 |
| NCT02753127 | Completed | Phase 3 | A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer | June 2016 | May 12, 2021 |
| NCT02921256 | Completed | Phase 2 | Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer | January 11, 2017 | September 20, 2023 |
| NCT03000374 | Completed | Phase 2 | Induction Therapy With Panitumumab + mFOLFOX-6 in Rectal Cancer and Quadruple Wild-type Mutation Before Surgery | May 30, 2017 | December 15, 2021 |
| NCT03043547 | Completed | Phase 2 | Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies | October 24, 2017 | March 8, 2022 |
| NCT03043729 | Completed | Phase 2 | mFOLFOX6 vs. mFOLFOX6 + Aflibercept as Neoadjuvant Treatment in MRI-defined T3-rectal Cancer | March 6, 2017 | June 1, 2022 |
| NCT03085914 | Completed | Phase 1/Phase 2 | A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723) | May 2, 2017 | July 13, 2020 |
| NCT03121807 | Completed | N/A | Home Parenteral Nutrition for Malnourished Unresectable Stage IV Gastric Cancer | September 1, 2014 | June 1, 2019 |
| NCT03131973 | Completed | Phase 1 | Effects of Concomitant Administration of BMS-986195 on Methotrexate, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin | May 13, 2017 | November 10, 2017 |
| NCT03184870 | Completed | Phase 1/Phase 2 | A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors | August 8, 2017 | June 14, 2023 |
| NCT03314935 | Completed | Phase 1/Phase 2 | A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors | November 21, 2017 | November 28, 2022 |
| NCT03336216 | Completed | Phase 2 | A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer | December 19, 2017 | June 1, 2023 |
| NCT03374254 | Completed | Phase 1 | Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651) | February 16, 2018 | July 18, 2023 |
| NCT03402087 | Completed | Phase 1 | A Study to Investigate BMS-986165 and Methotrexate in Healthy Male Patients | January 8, 2018 | March 25, 2018 |
| NCT03414983 | Completed | Phase 2/Phase 3 | An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread | February 20, 2018 | December 28, 2022 |
| NCT03446872 | Completed | Post Marketing Surveillance Study for ONIVYDE® in South Korea | March 8, 2018 | August 29, 2020 | |
| NCT03750786 | Completed | Phase 3 | A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer | December 18, 2018 | November 18, 2022 |
| NCT03778593 | Completed | Phase 2 | FOLFIRINOX for 2nd-line Treatment of BTC | March 1, 2019 | January 14, 2021 |
| NCT03783936 | Completed | Phase 2 | Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas | January 24, 2019 | August 30, 2022 |
| NCT03883919 | Completed | Phase 1 | Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy | July 11, 2019 | July 2, 2022 |
| NCT04299880 | Completed | Phase 1 | Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols | February 24, 2020 | May 30, 2021 |
| NCT04752163 | Completed | Phase 1/Phase 2 | DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia | March 25, 2021 | November 8, 2023 |
| NCT05445440 | Completed | Phase 1 | A Study to Assess the Effects of BMS-986371 on the Drug Levels of Methotrexate in the Presence and Absence of Sulfasalazine | September 6, 2022 | November 23, 2022 |
| NCT05615012 | Completed | Phase 1 | A Study Investigating Interactions Between BMS-986322 and Rosuvastatin, Metformin and Methotrexate in Healthy Participants | November 11, 2022 | December 13, 2023 |
| NCT05047991 | Not yet recruiting | Phase 2 | Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma | October 2021 | November 2024 |
| NCT06139211 | Not yet recruiting | Phase 1/Phase 2 | A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors | November 30, 2023 | April 30, 2026 |
| NCT06381154 | Not yet recruiting | Phase 2 | Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advance or Metastatic Pancreatic Cancer | June 30, 2024 | July 4, 2029 |
| NCT06205485 | Not yet recruiting | Phase 3 | Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer | July 31, 2024 | June 30, 2030 |
| NCT05296005 | Not yet recruiting | Phase 1 | Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers | May 31, 2022 | December 31, 2024 |
| NCT05493332 | Not yet recruiting | Phase 2 | HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC | September 2022 | September 2024 |
| NCT06259058 | Not yet recruiting | Phase 1/Phase 2 | Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer | April 1, 2024 | December 1, 2027 |
| NCT04488159 | Not yet recruiting | Phase 3 | Immunoscore as Decision Guidance for Adjuvant Chemotherapy in Colon Cancer | December 1, 2024 | June 1, 2026 |
| NCT06317662 | Not yet recruiting | Phase 2 | Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia | July 31, 2024 | December 21, 2027 |
| NCT06268015 | Not yet recruiting | Phase 2 | Botensilimab and Balstilimab Optimization in Colorectal Cancer | July 2024 | July 2028 |
| NCT05009953 | Not yet recruiting | Phase 2 | Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer | September 2021 | August 2024 |
| NCT06447662 | Not yet recruiting | Phase 1 | A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. | July 28, 2024 | July 12, 2028 |
| NCT06124157 | Not yet recruiting | Phase 3 | A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL) | July 22, 2024 | December 1, 2030 |
| NCT04371224 | Recruiting | Phase 2 | NaliCap (Irinotecan Liposome (Nal-IRI)/Capecitabine) vs. NAPOLI (Nal-IRI/5-FU/LV) ) in Advanced Pancreatic Cancer | June 23, 2020 | December 31, 2025 |
| NCT05714553 | Recruiting | Phase 1/Phase 2 | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | March 8, 2023 | January 2025 |
| NCT04393584 | Recruiting | Phase 2/Phase 3 | FOLFIRINOX vs FLOT Chemotherapy for Resectable Gastric or Esophagogastric Junction Adenocarcinoma | January 29, 2019 | January 1, 2026 |
| NCT04430738 | Recruiting | Phase 1/Phase 2 | Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers | September 15, 2020 | October 31, 2025 |
| NCT06328738 | Recruiting | Phase 1 | ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer | June 1, 2024 | July 2028 |
| NCT04442984 | Recruiting | Phase 2 | FOLFOX6 Versus mFOLFIRINOX as First Line Chemotherapy in Metastatic Gastric Cancer or Esophagogastric Junction Adenocarcinoma (Type II-III) | November 3, 2019 | November 3, 2024 |
| NCT04703101 | Recruiting | Phase 1 | Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer | February 11, 2021 | October 15, 2026 |
| NCT04447352 | Recruiting | Phase 3 | HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT) | December 17, 2020 | May 1, 2027 |
| NCT04562558 | Recruiting | N/A | Biweekly Actinomycin-D Treatment or Multi-day Methotrexate Protocol in Low-risk Gestational Trophoblastic Neoplasia | September 29, 2020 | December 2025 |
| NCT04595929 | Recruiting | N/A | Oncological Benefits of Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients With T3-4 Gastric Cancer Cyt- | February 10, 2020 | January 10, 2029 |
| NCT04607421 | Recruiting | Phase 3 | A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer | December 21, 2020 | November 15, 2026 |
| NCT04615013 | Recruiting | Phase 1 | NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer | November 23, 2020 | October 31, 2025 |
| NCT05891171 | Recruiting | Phase 1 | Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers | October 13, 2023 | August 2025 |
| NCT05945823 | Recruiting | Phase 2 | Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors | July 13, 2023 | May 2025 |
| NCT05727163 | Recruiting | Phase 2 | FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients | July 29, 2022 | December 31, 2026 |
| NCT06011772 | Recruiting | Early Phase 1 | EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer | December 4, 2023 | December 4, 2026 |
| NCT05292664 | Recruiting | Phase 1 | Venetoclax Basket Trial for High Risk Hematologic Malignancies | March 29, 2023 | April 2, 2027 |
| NCT05843188 | Recruiting | Phase 2 | Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer | August 9, 2023 | October 24, 2026 |
| NCT05651594 | Recruiting | Phase 2 | Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma | March 7, 2023 | March 30, 2026 |
| NCT06028737 | Recruiting | Phase 2/Phase 3 | Total Neoadjuvant Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer | August 25, 2023 | December 2031 |
| NCT02997228 | Recruiting | Phase 3 | Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study | January 19, 2018 | November 30, 2024 |
| NCT05567835 | Recruiting | Phase 2 | A Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in Patients With Gastric or GEJ Cancer | March 6, 2024 | January 2029 |
| NCT05286814 | Recruiting | Phase 2 | M9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma | October 24, 2022 | December 31, 2028 |
| NCT03505320 | Recruiting | Phase 2 | A Study to Assess the Antitumor Activity, Safety, Pharmacokinetics and Biomarkers of Zolbetuximab (IMAB362) in Participants With Claudin (CLDN) 18.2 Positive, Metastatic or Advanced Unresectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma and Locoregional Gastric or GEJ Adenocarcinoma | June 29, 2018 | December 31, 2026 |
| NCT05564377 | Recruiting | Phase 2 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | April 7, 2023 | July 1, 2030 |
| NCT05253651 | Recruiting | Phase 3 | A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer | October 24, 2022 | April 30, 2028 |
| NCT05239741 | Recruiting | Phase 3 | Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66) | April 2, 2022 | November 10, 2026 |
| NCT05146739 | Recruiting | Phase 1 | Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory and That Expresses E-selectin Ligand on the Cell Membrane | October 10, 2023 | December 31, 2024 |
| NCT05067283 | Recruiting | Phase 1 | A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001) | December 17, 2021 | August 19, 2026 |
| NCT05482893 | Recruiting | Phase 1/Phase 2 | PT886 For Treatment of Patients With Metastatic/Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinoma (the TWINPEAK Study) | March 15, 2023 | April 2026 |
| NCT05062317 | Recruiting | Phase 2 | ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases | April 26, 2022 | February 28, 2026 |
| NCT05472259 | Recruiting | Phase 2 | A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC) | May 25, 2022 | December 31, 2027 |
| NCT03684980 | Recruiting | Early Phase 1 | LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma | November 14, 2018 | November 2025 |
| NCT05032183 | Recruiting | Phase 1/Phase 2 | Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | February 17, 2022 | July 1, 2025 |
| NCT03764553 | Recruiting | Phase 2 | Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer | May 1, 2019 | August 1, 2024 |
| NCT06219941 | Recruiting | Phase 2 | AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 | December 13, 2023 | January 19, 2027 |
| NCT05417386 | Recruiting | Phase 1 | FOLFIRINOX + NIS793 in Pancreatic Cancer | August 9, 2022 | May 1, 2025 |
| NCT05026905 | Recruiting | Phase 2 | A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer | December 28, 2021 | December 31, 2027 |
| NCT03800693 | Recruiting | Phase 2 | 2 Versus 6 Hour Oxaliplatin Infusions in Patients With Gastrointestinal Cancers | March 14, 2019 | November 4, 2024 |
| NCT03872947 | Recruiting | Phase 1 | A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors | April 26, 2019 | March 2025 |
| NCT05863195 | Recruiting | Phase 3 | Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial | October 19, 2023 | June 30, 2034 |
| NCT04005339 | Recruiting | Phase 2 | NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer | July 29, 2019 | July 31, 2024 |
| NCT05382442 | Recruiting | Phase 2 | A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer | July 27, 2022 | December 25, 2026 |
| NCT04949256 | Recruiting | Phase 3 | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014) | July 28, 2021 | December 29, 2025 |
| NCT03203525 | Recruiting | Phase 1 | Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer | June 23, 2020 | December 31, 2026 |
| NCT05379595 | Recruiting | Phase 1/Phase 2 | A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer | July 29, 2022 | April 27, 2027 |
| NCT04205968 | Recruiting | Phase 2 | Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers | June 1, 2020 | June 16, 2025 |
| NCT04864067 | Recruiting | Phase 2 | No Operation After Short Course Radiotherapy Followed By Consolidation Chemotherapy In Locally Advanced Rectal Cancer | June 9, 2021 | May 30, 2025 |
| NCT05329766 | Recruiting | Phase 2 | A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies | June 10, 2022 | June 2027 |
| NCT04248452 | Recruiting | Phase 3 | Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body | May 26, 2020 | March 31, 2028 |
| NCT04762953 | Recruiting | Phase 2 | Study of Sequential Systemic Therapy + Intraperitoneal Paclitaxel in Gastric/GEJ Peritoneal Carcinomatosis | February 18, 2021 | June 2025 |
| NCT04329494 | Recruiting | Phase 1 | PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer | August 21, 2020 | December 30, 2025 |
| NCT04354662 | Recruiting | Phase 2 | Toripalimab Combined With FLOT Neoadjuvant Chemotherapy in Patients With Resectable Gastric Cancer | September 26, 2019 | June 30, 2024 |
| NCT04361708 | Recruiting | Phase 1 | Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies | May 8, 2020 | May 2027 |
| NCT04008030 | Recruiting | Phase 3 | A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) | August 5, 2019 | June 10, 2026 |
| NCT03899155 | Recruiting | Phase 2 | Pan Tumor Rollover Study | August 9, 2019 | August 25, 2029 |
| NCT05647122 | Recruiting | Phase 1 | First in Human Study of AZD9592 in Solid Tumors | December 22, 2022 | October 29, 2025 |
| NCT05412082 | Recruiting | Phase 1 | SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer | October 5, 2022 | October 2027 |
| NCT03977233 | Recruiting | Phase 2 | Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer | June 12, 2019 | January 2030 |
| NCT05688215 | Suspended | Phase 1/Phase 2 | Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma | March 7, 2023 | May 1, 2026 |
| NCT00755118 | Terminated | Phase 2 | Lohp, 5-Fu/Lv and Bevacizumab, Alternative With Cpt-11, 5-Fu/Lv and Cetuximab In Metastatic Crc | October 2008 | August 2012 |
| NCT00037180 | Terminated | Phase 2 | For Prevention of Diarrhea in Patients Diagnosed With Metastatic Colorectal Cancer Treated With Chemotherapy | April 2002 | January 2003 |
| NCT03050814 | Terminated | Phase 2 | Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004 | April 5, 2017 | August 25, 2021 |
| NCT03099486 | Terminated | Phase 2 | Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRC | October 6, 2017 | June 2, 2020 |
| NCT03136406 | Terminated | Phase 1/Phase 2 | QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy | August 11, 2017 | November 1, 2019 |
| NCT01479465 | Terminated | Phase 2 | Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma | December 2011 | February 2015 |
| NCT01258634 | Terminated | Phase 1 | A Study of Pre-Operative Treatment of Newly-Diagnosed, Surgically-Resectable Osteosarcoma With Doxorubicin, Ifosfamide, Etoposide, and Cisplatin With Early Metabolic Assessment of Response | July 2010 | November 2011 |
| NCT03300544 | Terminated | Phase 1 | Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer | May 14, 2019 | March 22, 2022 |
| NCT03368859 | Terminated | Phase 2 | A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab | March 20, 2018 | December 18, 2019 |
| NCT03387098 | Terminated | Phase 1/Phase 2 | QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy | December 28, 2017 | January 15, 2019 |
| NCT01014767 | Terminated | Phase 3 | Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors | November 2009 | January 2014 |
| NCT00889343 | Terminated | Phase 2 | Study to Evaluate the Effects of Sorafenib if Combined With Chemotherapy (FOLFOX6 or FOLFIRI) in the Second-Line Treatment of Colorectal Cancer | March 2009 | December 2012 |
| NCT03500874 | Terminated | Phase 3 | Adjuvant Systemic Chemotherapy With or Without HAI-FUDR in Patients With Resected CRLM | May 28, 2018 | August 31, 2021 |
| NCT03515941 | Terminated | Early Phase 1 | Postoperative Chemoradiation or Chemotherapy After Preoperative Chemotherapy for Gastric Cancers | June 22, 2018 | June 18, 2020 |
| NCT00673179 | Terminated | N/A | Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient Chemotherapy | May 2008 | November 2010 |
| NCT00642746 | Terminated | Phase 2 | Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC) | March 2008 | December 2011 |
| NCT03678428 | Terminated | Phase 3 | FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM | December 31, 2021 | December 31, 2022 |
| NCT00634322 | Terminated | Phase 2 | High Dose Methotrexate With Leucovorin Rescue With or Without Glucarpidase in Osteosarcoma | October 2008 | April 2009 |
| NCT00632827 | Terminated | Phase 2 | Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak) | July 1, 2008 | June 23, 2016 |
| NCT03878524 | Terminated | Phase 1 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | April 1, 2020 | December 10, 2020 |
| NCT00539617 | Terminated | Phase 2 | Chemotherapy & Erlotinib in Treating Patients w/ Esophageal or Gastroesophageal Cancer That Cannot Be Removed by Surgery | October 5, 2007 | May 12, 2011 |
| NCT00537823 | Terminated | Phase 2 | Pre- and Post-operative FOLFOX Based Therapy for Patients With Colorectal Cancer With Liver Involvement | June 2007 | July 2011 |
| NCT00508872 | Terminated | Phase 2 | Folfox-B Study for Patients With Colorectal Liver Metastases | November 2005 | June 2009 |
| NCT00449163 | Terminated | Phase 2 | Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer | March 1, 2006 | March 2010 |
| NCT00448682 | Terminated | Phase 2 | Combination Chemotherapy as First-Line Therapy in Treating Patients With Stage IV Gastric Cancer That Cannot Be Removed By Surgery | June 2005 | March 2010 |
| NCT00335140 | Terminated | Phase 2 | Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma | August 23, 2007 | July 2015 |
| NCT00309517 | Terminated | Phase 3 | Randomized Study on Neoadjuvant Radio-Chemotherapy in Rectal Carcinoma Dukes B and C | July 1997 | |
| NCT00227617 | Terminated | Phase 2/Phase 3 | Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors | June 8, 2005 | February 2016 |
| NCT00155883 | Terminated | Phase 2 | Bi-Weekly Docetaxel Plus 24-Hour Infusion of High-Dose 5-Fluorouracil / Leucovorin (HDFL) for Inoperable Advanced or Metastatic Gastric Cancer | June 2004 | July 2005 |
| NCT00126191 | Terminated | Phase 2 | Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma | July 2005 | June 2011 |
| NCT00077233 | Terminated | Phase 3 | FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum | December 2003 | June 2010 |
| NCT00065117 | Terminated | Phase 2 | Safety, Tolerability and Efficacy of ZD6126 in Combination With Oxaliplatin, 5-Fluorouracil and Leucovorin in Subjects With Metastatic Colorectal Cancer. | September 2003 | February 2004 |
| NCT00044785 | Terminated | Phase 1 | Phase I Study of PN401, Fluorouracil, Leucovorin and CPT-11 in Patients With Solid Tumors | August 2002 | March 2004 |
| NCT02420717 | Terminated | Phase 2 | Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia | July 15, 2015 | January 20, 2021 |
| NCT01964755 | Terminated | Phase 2 | Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma | April 21, 2009 | June 7, 2018 |
| NCT05546411 | Terminated | Phase 2 | A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer | January 6, 2023 | October 13, 2023 |
| NCT02676323 | Terminated | Phase 1 | Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome | May 3, 2016 | April 9, 2018 |
| NCT00040391 | Terminated | Phase 2 | A Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Previously Untreated Metastatic Colorectal Cancer | June 2002 | |
| NCT01522612 | Terminated | Phase 2 | Colorectal Cancer (CRC) Cetuximab Elderly Frail | April 2013 | January 2015 |
| NCT02500940 | Unknown status | Phase 3 | Comparison the Effects of Different Neoadjuvant Chemotherapy Regimen on Acute Toxicity, Tumor Response, and Survival in Patients With Advanced Nasopharyngeal Carcinoma | May 2015 | May 2021 |
| NCT01652196 | Unknown status | Phase 2 | Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer | November 14, 2012 | December 31, 2019 |
| NCT02515734 | Unknown status | Phase 2 | A Study of FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab | August 2015 | June 2020 |
| NCT03711240 | Unknown status | Phase 2 | The Efficacy of Bevacizumab Combined With m-FOLFOXIRI in Borderline Resectable Colorectal Liver Metastases | January 8, 2019 | October 30, 2020 |
| NCT02099175 | Unknown status | Phase 2 | Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Operable Patients | November 2013 | January 2024 |
| NCT01529164 | Unknown status | Phase 2 | Efficacy and Safety Study of Recombinant Endostatin Combined With Chemotherapy to Treat Advanced Colorectal Cancer | October 2011 | September 2014 |
| NCT02099188 | Unknown status | Phase 2 | Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Inoperable Patients | November 2013 | January 2024 |
| NCT02624726 | Unknown status | Phase 2 | Trial in Metastatic Colorectal Cancer With FOLFIRI Plus Aflibercept as First Line Treatment | January 2016 | March 2019 |
| NCT01494363 | Unknown status | Phase 2 | Phase II Study of FOLFOXIRI in Patients With Locally Advanced or Metastatic Biliary Tract Cancer | October 2011 | December 2013 |
| NCT01308086 | Unknown status | Phase 3 | Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX for Stage II or Stage III Colon Cancer | October 2010 | December 2017 |
| NCT04689347 | Unknown status | Phase 1 | 5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer. | January 1, 2021 | January 2023 |
| NCT03703063 | Unknown status | Phase 1 | Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer | September 17, 2018 | September 17, 2022 |
| NCT03522649 | Unknown status | Phase 3 | A Phase III Clinical Study of Napabucasin (GB201) Plus FOLFIRI in Adult Patients With Metastatic Colorectal Cancer | April 12, 2018 | November 2021 |
| NCT03503604 | Unknown status | Phase 1 | A Study of Anti-VEGF Monoclonal Antibody hPV19 in Patients With Solid Tumors | May 1, 2018 | March 1, 2019 |
| NCT00323583 | Unknown status | Phase 2 | Weekly Dosing of an Integrative Chemotherapy Combination to Treat Advanced Pancreatic Cancer | May 2006 | |
| NCT00337389 | Unknown status | Phase 3 | Phase III Randomized Study of 5-FU, CoFactor, and Avastin vs. 5-FU, LV and Avastin for First-Line Colorectal Cancer. | May 2006 | |
| NCT01150045 | Unknown status | Phase 3 | Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery | June 2010 | |
| NCT02935764 | Unknown status | Phase 3 | FOLFIRI Versus Irinotecan as Second-line Treatment in Metastatic Colorectal Cancer Patients | October 2016 | |
| NCT04072198 | Unknown status | Phase 2 | Nivolumab Plus FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced Colorectal Cancer RASm/BRAFm Patients | September 26, 2019 | September 2022 |
| NCT01231802 | Unknown status | Phase 2 | Study of Eniluracil + 5-Fluorouracil (5-FU) + Leucovorin Versus Capecitabine in Metastatic Breast Cancer | April 2011 | January 2013 |
| NCT03791905 | Unknown status | Phase 2 | PET Imaging-guided Chemoradiotherapy in Esophageal Squamous Cell Carcinoma | January 15, 2019 | December 2023 |
| NCT02376452 | Unknown status | Phase 2 | Phase II Study of 2-weekly RAILIRI Versus FOLFIRI as Second-line Treatment in Advanced Colorectal Cancer Patients | September 2014 | December 2016 |
| NCT03607643 | Unknown status | Phase 1/Phase 2 | A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies | January 15, 2019 | December 15, 2020 |
| NCT02415699 | Unknown status | Phase 2/Phase 3 | DC-CIK Immunotherapy Plus Chemotherapy vs Chemotherapy Alone in the Adjuvant Treatment of Stage III Colorectal Cancer | August 2015 | July 2020 |
| NCT02959541 | Unknown status | N/A | PK/PD Investigation of Calciumfolinat in Blood, Tumor and Adjacent Mucosa in Patient With Colon Cancer | September 2016 | December 31, 2022 |
| NCT03167112 | Unknown status | Phase 2 | A Study of Administering FOLFIRINOX Before Surgery For Potentially Curable Pancreatic Cancer | July 3, 2017 | May 2018 |
| NCT02453464 | Unknown status | Phase 1 | A Phase Ib Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection Plus FOLFIRI in Chinese Patients With Metastatic Colorectal Cancer | August 2015 | |
| NCT03169777 | Withdrawn | Phase 1/Phase 2 | QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC | August 2018 | March 2019 |
| NCT03563170 | Withdrawn | Phase 1/Phase 2 | QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine | May 25, 2018 | August 23, 2019 |
| NCT03563144 | Withdrawn | Phase 2 | QUILT-3.088: NANT Pancreatic Cancer Vaccine | August 2018 | December 30, 2019 |
| NCT03554109 | Withdrawn | Phase 2 | QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine | September 2018 | December 2021 |
| NCT01302613 | Withdrawn | Phase 1/Phase 2 | Altered Chemotherapy Sequencing During Neoadjuvant Therapy for Patients With Stage II or III Rectal Adenocarcinoma | March 2011 | November 2012 |
| NCT02785068 | Withdrawn | Phase 1/Phase 2 | Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer | July 2016 | October 2018 |
| NCT02046538 | Withdrawn | Phase 2 | Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer | February 2014 | February 2018 |
| NCT03197584 | Withdrawn | Phase 1/Phase 2 | QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy | December 2017 | April 2019 |
| NCT03197571 | Withdrawn | Phase 1/Phase 2 | QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy | December 2017 | March 2019 |
| NCT02296671 | Withdrawn | Phase 2 | Personalized Therapy for Esophagogastric Cancer Using Thymidylate Synthase Genetic Markers | February 2015 | February 2022 |
| NCT03175666 | Withdrawn | Phase 1/Phase 2 | QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy | December 2017 | March 2019 |
| NCT03169790 | Withdrawn | Phase 1/Phase 2 | QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL | December 2017 | March 2019 |
| NCT02856867 | Withdrawn | Phase 2 | Nintedanib Plus mFOLFOX6 for Previously Untreated Metastatic Esophagogastric Adenocarcinoma (MEGAN) | December 2016 | |
| NCT03169764 | Withdrawn | Phase 1/Phase 2 | QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy | December 2017 | March 2019 |
| NCT03169738 | Withdrawn | Phase 1/Phase 2 | QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors | February 2018 | March 2019 |
| NCT03167177 | Withdrawn | Phase 1/Phase 2 | QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy | December 2017 | March 2019 |
| NCT00233623 | Withdrawn | Phase 2 | Irinotecan, 5-Fluorouracil and Leucovorin With or Without Iressa in the Treatment of Metastatic Colorectal Cancer | July 2004 | January 2006 |
| NCT04430985 | Withdrawn | Phase 2 | FOLFOX + Immunotherapy With Intrahepatic Oxaliplatin for Patients With Metastatic Colorectal Cancer | September 30, 2020 | September 6, 2021 |
| NCT03069950 | Withdrawn | Phase 2 | Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver | February 28, 2017 | May 16, 2019 |
| NCT03167164 | Withdrawn | Phase 1/Phase 2 | QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy | December 2017 | March 2019 |
| NCT00577109 | Withdrawn | Phase 2 | A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer. | December 2007 | June 2012 |